ReviewTissue engineering. Part C, Methods2021
Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
Review in Tissue engineering. Part C, Methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Article
- Tracking Spatiotemporal Extracellular Matrix Evolution and Tissue Fusion in 3D Microtissues via Click Chemistry-Based Metabolic Labelling.Advanced healthcare materials · 2026Article
- Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum.Nature communications · 2026Article
- Osteoarthritis as a systemic disease.Nature reviews. Rheumatology · 2026Review
- 3D-bioprinting for joint regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Organ-on-chip technologies: Novel tools with the potential to revolutionize osteoarthritis research and clinical development.Osteoarthritis and cartilage open · 2025Review
- Platelet-rich plasma-contained drug delivery systems to treat orthopedic injuries.International journal of pharmaceutics: X · 2025Review
- An Animal-Free Patient-Derived Tissue-Mimetic Biochip Model of the Human Synovial Membrane for Human-Relevant Osteoarthritis Research.Advanced healthcare materials · 2025Article
- Aging-associated Increase of GATA4 levels in Articular Cartilage is Linked to Impaired Regenerative Capacity of Chondrocytes and Osteoarthritis.bioRxiv : the preprint server for biology · 2025Article
- The Role ofBiomolecules · 2025Review
- Tuning the Response of Synthetic Mechanogenetic Gene Circuits Using Mutations in TRPV4.Tissue engineering. Part A · 2025Article
- Synoviocyte-chondrocyte triculture model for early-stage PTOA: fibronectin fragment-induced catabolic effectsFrontiers in bioengineering and biotechnology · 2025Article
- Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis.Advanced healthcare materials · 2024Article
- A scoping review of statistical methods to investigate colocalization between genetic associations and microRNA expression in osteoarthritis.Osteoarthritis and cartilage open · 2024Article
- Serum Sirt6 as a Potential Biomarker for Osteoarthritis and its Correlation with IL-6 Alterations.Indian journal of orthopaedics · 2024Article
- Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states.Stem cell research & therapy · 2024Review
- Article
- Article
- Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.PloS one · 2024Article
- Transplantation of Gelatin Microspheres Loaded with Wharton's Jelly Derived Mesenchymal Stem Cells Facilitates Cartilage Repair in Mice.Tissue engineering and regenerative medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Osteoarthritis (OA) is a painful and disabling disease that affects millions of people worldwide. Symptom-alleviating treatments exist, although none with long-term efficacy. Furthermore, there are currently no disease-modifying OA drugs (DMOADs) with demonstrated efficacy in OA patients, which is, in part, attributed to a lack of full understanding of the pathogenesis of OA. The inability to translate findings from basic research to clinical applications also highlights the deficiencies in the available OA models at simulating the clinically relevant pathologies and responses to treatments in humans. In this review, the current status in the development of DMOADs will be first presented, with special attention to those in Phase II-IV clinical trials. Next, current
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.